AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

Oncogene

Volumn 23, Issue 34, 2004, Pages 5853-5857

  Altomare, Deborah A ^a   Hui, Qin Wang ^a   Skele, Kristine L ^a   De Rienzo, Assunta ^a   Klein Szanto, Andres J ^a   Godwin, Andrew K ^a   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

AKT; LY294002; mTOR; Ovarian cancer; Protein kinase B; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTIBODY; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STAINING; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL DIVISION; CHROMONES; CISPLATIN; ENZYME INHIBITORS; FEMALE; HUMANS; MORPHOLINES; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TUMOR CELLS, CULTURED;

FALLOPIA; MAMMALIA;

EID: 4143111260     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207721     Document Type: Article

References (18)

1. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KS, Hoffman JP and Testa JR. (2002). J. Cell Biochem., 87, 470-476.
2. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY and Slamon DJ. (2003). Cancer Res., 63, 196-206.
3. Brognard J, Clark AS, Ni Y and Dennis PA. (2001). Cancer Res., 61, 3986-3997.
4. Cantley LC. (2002). Science, 296, 1655-1657.
5. Dhawan P, Singh AB, Ellis DL and Richmond A. (2002). Cancer Res., 62, 7335-7342.
6. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS and Muschel RJ. (2002). Clin. Cancer Res., 8, 885-892.
7. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB. (2002). Cancer Res., 62, 1087-1092.
8. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA. (1999). J. Biol. Chem., 274, 21528-21532.
9. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL. (2001). Proc. Natl. Acad. Sci. USA, 98, 10031-10033.
10. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J. (2000). Anticancer Res., 20, 407-416.
11. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L and Parsons R. (2001). Proc. Natl. Acad. Sci. USA, 98, 10320-10325.
12. Pullen N and Thomas G. (1997). FEBS Lett., 410, 78-82.
13. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW. (1999). Nat. Genet., 21, 99-102.
14. Sonenberg N and Gingras AC. (1998). Curr. Opin. Cell. Biol., 10, 268-275.
15. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ. (2001). Am. J. Pathol., 159, 431-437.
16. Testa JR and Bellacosa A. (2001). Proc. Natl. Acad. Sci. USA, 98, 10983-10985.
17. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV and Cheng JQ. (2000). Oncogene, 19, 2324-2330.
18. West KA, Sianna Castillo S and Dennis PA. (2002). Drug Resist Update, 5, 234-248.